News
PRLD
4.040
+4.39%
0.170
Prelude Therapeutics: Leading the Oncology Market with Innovative SMARCA2 Targeting Drug PRT3789
TipRanks · 14h ago
Weekly Report: what happened at PRLD last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at PRLD last week (0408-0412)?
Weekly Report · 04/15 09:24
Prelude Therapeutics Announces CFO Transition and Interim Appointment
TipRanks · 04/10 20:24
Prelude Therapeutics Disclosed Laurent Chardonnet Will No Longer Serve As CFO
Benzinga · 04/10 20:11
PRELUDE THERAPEUTICS INC - ON APRIL 8, CO AND LAURENT CHARDONNET AGREED THAT HE WILL NO LONGER SERVE AS CO'S CFO
Reuters · 04/10 20:08
PRELUDE THERAPEUTICS INC - APPOINTED BRYANT D. LIM AS INTERIM CFO
Reuters · 04/10 20:08
Prelude Therapeutics: A Buy Rating on the Horizon with Promising Preclinical Data and Upcoming Clinical Trials
TipRanks · 04/10 18:35
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Barchart · 04/09 15:35
Weekly Report: what happened at PRLD last week (0401-0405)?
Weekly Report · 04/08 09:26
Weekly Report: what happened at PRLD last week (0325-0329)?
Weekly Report · 04/01 09:26
Weekly Report: what happened at PRLD last week (0318-0322)?
Weekly Report · 03/25 09:27
Weekly Report: what happened at PRLD last week (0311-0315)?
Weekly Report · 03/18 09:26
Despite Recent Gains, Prelude Therapeutics Insiders Are Still Down US$19k
Insiders purchased US$117.0k worth of Prelude Therapeutics Incorporated shares over the past year. The company's share price has risen 11% in the last week. Insiders made losses of US$19k since the purchase of shares. In the last 12 months Prelude TherAPEutics insiders were buying shares, but not selling. It's a good sign to see if insiders are buying shares at higher prices. Prelude Therapedutics insiders own 5.9% of the company.
Simply Wall St · 03/14 10:03
Prelude Therapeutics Initiated at Market Outperform by JMP Securities
Dow Jones · 03/13 09:30
Prelude Therapeutics Price Target Announced at $7.00/Share by JMP Securities
Dow Jones · 03/13 09:30
JMP Securities Initiates Coverage On Prelude Therapeutics with Market Outperform Rating, Announces Price Target of $7
Benzinga · 03/13 09:20
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)
TipRanks · 03/13 04:30
Weekly Report: what happened at PRLD last week (0304-0308)?
Weekly Report · 03/11 09:26
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Prel Prelude Therapeutics Incorporated is a clinical-stage precision oncology company. The Company's preclinical data will be presented at the American Association for Cancer Research Annual Meeting 2024. The company's three posters will be accepted for presentation at the AACR meeting.
Barchart · 03/05 15:45
More
Webull provides a variety of real-time PRLD stock news. You can receive the latest news about Prelude Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PRLD
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.